Thread Content
On May 12, the project for a caprolactone and polycaprolactone production facility at Weibojie Biomaterials (Zhejiang) Co., Ltd. was made public. The total investment in the project is 1.05 billion yuan; 112 mu of new land will be acquired in Shaoxing’s Binhai New City to build facilities including office buildings, underground garages, laboratories, factories, and systems for the treatment of waste materials. Focusing on the long-standing bottleneck in China’s field of biodegradable materials, this project adopts a lactide-polylactide production process based on independently developed continuous-flow technology, thereby overcoming the limitations of traditional reactor-based processes and addressing the challenges associated with large-scale production. It involves building a production line capable of producing 30,000 tons per year of lactide monomer as well as various grades of polylactide products (the implementation will take place in two phases: in the first phase, all construction work will be completed along with a production line capable of handling 10,000 tons per year; in the second phase, an additional production line with a capacity of 20,000 tons per year will be added). Additionally, 90,000 tons of acetic acid will be produced annually as a by-product. ε-Caprolactone is a cyclic ester compound that serves as an important monomer for the synthesis of polyester and polyether polymers; it undergoes ring-opening polymerization to produce the biodegradable polyester polycaprolactone (PCL). PCL possesses excellent biocompatibility and degradability, and is widely used in medical fields such as medical devices, artificial bones, and vascular stents, as well as in industrial fields such as elastomers, synthetic leather, adhesives, coatings, and fishing nets. Furthermore, the composite solid electrolyte membrane made of PCL endows all-solid-state lithium batteries with high lithium ion conductivity, excellent charge-discharge cycle performance, and high safety, outperforming materials such as PEO; it is the key material for the next generation of all-solid-state lithium batteries, with cost under control. Weibojie Biomedical Materials (Zhejiang) Co., Ltd. was established in 2021 and is located in Shaoxing City, Zhejiang Province. The company is dedicated to the research, development, production, and sales of environmentally degradable polymers that are in high demand by strategic emerging industries such as new materials, new energy, and biomedicine, all in pursuit of the goal of carbon neutrality. In July 2024, the company’s project to produce 30,000 tons per year of caprolactone monomer and various grades of polycaprolactone products was made public. The project is divided into zones A, B, and C, and it covers multiple types of construction applications ； In September 2024, the construction of the project officially began; the construction period spans from 2024 to 2026, with full operation planned to start in early July 2026.